Korro Bio Statistics
Total Valuation
Korro Bio has a market cap or net worth of $177.77 million. The enterprise value is $102.78 million.
Important Dates
The last earnings date was Tuesday, August 12, 2025, before market open.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Korro Bio has 9.39 million shares outstanding. The number of shares has increased by 65.89% in one year.
| Current Share Class | 9.39M |
| Shares Outstanding | 9.39M |
| Shares Change (YoY) | +65.89% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 6.41% |
| Owned by Institutions (%) | 63.29% |
| Float | 4.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.22 |
| Forward PS | n/a |
| PB Ratio | 1.54 |
| P/TBV Ratio | 1.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.98, with a Debt / Equity ratio of 0.39.
| Current Ratio | 5.98 |
| Quick Ratio | 5.67 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -58.34% and return on invested capital (ROIC) is -31.09%.
| Return on Equity (ROE) | -58.34% |
| Return on Assets (ROA) | -28.65% |
| Return on Invested Capital (ROIC) | -31.09% |
| Return on Capital Employed (ROCE) | -60.37% |
| Revenue Per Employee | $60,394 |
| Profits Per Employee | -$878,413 |
| Employee Count | 104 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Korro Bio has paid $95,000 in taxes.
| Income Tax | 95,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.37% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -47.37% |
| 50-Day Moving Average | 14.03 |
| 200-Day Moving Average | 27.86 |
| Relative Strength Index (RSI) | 66.55 |
| Average Volume (20 Days) | 143,098 |
Short Selling Information
The latest short interest is 1.19 million, so 12.67% of the outstanding shares have been sold short.
| Short Interest | 1.19M |
| Short Previous Month | 1.10M |
| Short % of Shares Out | 12.67% |
| Short % of Float | 24.33% |
| Short Ratio (days to cover) | 9.78 |
Income Statement
In the last 12 months, Korro Bio had revenue of $6.28 million and -$91.36 million in losses. Loss per share was -$9.76.
| Revenue | 6.28M |
| Gross Profit | 6.28M |
| Operating Income | -98.55M |
| Pretax Income | -81.17M |
| Net Income | -91.36M |
| EBITDA | -93.98M |
| EBIT | -98.55M |
| Loss Per Share | -$9.76 |
Full Income StatementBalance Sheet
The company has $96.36 million in cash and $44.63 million in debt, giving a net cash position of $74.99 million or $7.99 per share.
| Cash & Cash Equivalents | 96.36M |
| Total Debt | 44.63M |
| Net Cash | 74.99M |
| Net Cash Per Share | $7.99 |
| Equity (Book Value) | 115.10M |
| Book Value Per Share | 12.26 |
| Working Capital | 85.46M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$67.27 million and capital expenditures -$6.59 million, giving a free cash flow of -$73.86 million.
| Operating Cash Flow | -67.27M |
| Capital Expenditures | -6.59M |
| Free Cash Flow | -73.86M |
| FCF Per Share | -$7.86 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -1,569.08% |
| Pretax Margin | -1,452.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Korro Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -65.89% |
| Shareholder Yield | -65.89% |
| Earnings Yield | -51.39% |
| FCF Yield | -41.55% |
Analyst Forecast
The average price target for Korro Bio is $96.71, which is 410.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $96.71 |
| Price Target Difference | 410.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 123.56% |
| EPS Growth Forecast (5Y) | -6.23% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Korro Bio has an Altman Z-Score of -0.68 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.68 |
| Piotroski F-Score | 1 |